FDA approves Alexion Pharma’s metabolic disorder drug


(Reuters) – The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc’s Strensiq, a treatment for a rare kind of metabolic disorder.

Strensiq is designed to treat perinatal, infantile and juvenile-onset hypophosphatasia, a genetic and potentially fatal disorder that affects multiple systems of the body, which could lead to severe complications. (http://1.usa.gov/1W9KuRH)

(Reporting by Samantha Kareen Nair in Bengaluru; Editing by Savio D’Souza)